Target
Mitogen-activated protein kinase 1
Ligand
BDBM120095
Substrate
n/a
Meas. Tech.
ChEMBL_1824544 (CHEMBL4324308)
Kd
1.6±n/a nM
Citation
 Ward, RAAnderton, MJBethel, PBreed, JCook, CDavies, EJDobson, ADong, ZFairley, GFarrington, PFeron, LFlemington, VGibbons, FDGraham, MAGreenwood, RHanson, LHopcroft, PHowells, RHudson, JJames, MJones, CDJones, CRLi, YLamont, SLewis, RLindsay, NMcCabe, JMcGuire, TRawlins, PRoberts, KSandin, LSimpson, ISwallow, STang, JTomkinson, GTonge, MWang, ZZhai, B Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC). J Med Chem 62:11004-11018 (2019) [PubMed]  Article 
Target
Name:
Mitogen-activated protein kinase 1
Synonyms:
ERK2 | ERT1 | Extracellular signal-regulated kinase 2 | Extracellular signal-regulated kinase 2 (ERK-2) | Extracellular signal-regulated kinase 2 (ERK2) | MAP Kinase 2/ERK2 | MAPK 2 | MAPK1 | MK01_HUMAN | Mitogen activated kinase 1 (ERK-2) | Mitogen-activated protein kinase 1 (ERK-2) | Mitogen-activated protein kinase 1 (ERK2) | Mitogen-activated protein kinase 2 | PRKM1 | PRKM2 | p42-MAPK
Type:
Ser/Thr Protein Kinase
Mol. Mass.:
41392.76
Organism:
Homo sapiens (Human)
Description:
P28482
Residue:
360
Sequence:
MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS
  
Inhibitor
Name:
BDBM120095
Synonyms:
US10525036, Example GDC-0994 | US10934304, Example GDC-0994 | US8697715, 39 | US9259470, 39
Type:
Small organic molecule
Emp. Form.:
C21H18ClFN6O2
Mol. Mass.:
440.858
SMILES:
Cn1nccc1Nc1nccc(n1)-c1ccn([C@H](CO)c2ccc(Cl)c(F)c2)c(=O)c1 |r|
Structure:
Search PDB for entries with ligand similarity: